Lantheus Holdings Stock Fair Value Calculator – Thrivent Financial drastically reduces Lantheus Holdings’ shares in 2nd quarter

☀️Trending News

Lantheus Holdings ($NASDAQ:LNTH), Inc. is a leading provider of diagnostic imaging and nuclear medicine products, serving the healthcare industry globally. With a focus on developing innovative solutions for the detection and treatment of various diseases, the company has established itself as a trusted partner for physicians and patients alike.

However, in the second quarter of this year, Lantheus Holdings faced a significant decrease in its shares as one of its major shareholders, Thrivent Financial for Lutherans, drastically reduced its stake in the company. However, according to recent filings with the Securities and Exchange Commission, the organization sold off 90.9% of its holdings in the company during the second quarter. This move by Thrivent Financial for Lutherans has raised concerns among investors and analysts about the future prospects of Lantheus Holdings. The reasons behind Thrivent Financial for Lutherans’ decision to reduce its stake in Lantheus Holdings are not entirely clear. However, it could be attributed to a combination of factors, including changes in their investment strategy or a lack of confidence in the company’s performance and outlook. Despite this setback, Lantheus Holdings remains focused on its mission to improve patient outcomes through its innovative diagnostic imaging solutions.

Additionally, they have continued to invest in research and development to expand their product portfolio and drive future growth. In conclusion, while the drastic reduction in shares by Thrivent Financial for Lutherans may have caused some concern, Lantheus Holdings remains a strong and reputable company in the healthcare industry. As the company continues to pursue its growth strategy, investors will be closely watching to see how this recent development will impact its future performance and stock price.

Share Price

Lantheus Holdings, a leading provider of diagnostic imaging and nuclear medicine for healthcare professionals, saw its stock open at $106.03 and close at $107.36, representing a 2.81% increase from the previous day’s closing price of $104.43. This significant reduction in shares by Thrivent Financial raises questions about their confidence in Lantheus Holdings’ future performance. It also highlights the potential concerns that Thrivent Financial may have regarding the company’s financial stability or growth prospects.

However, it should be noted that this move may also be a strategic decision by Thrivent Financial to diversify its investment portfolio and reallocate its assets elsewhere. The impact of this news on Lantheus Holdings’ stock was evident as it experienced a decline during after-hours trading on Thursday and a slight increase on Friday. The sudden decrease in shares by Thrivent Financial may have caused some uncertainty among investors, leading to the fluctuation in stock price. In conclusion, Thrivent Financial’s decision to drastically reduce its shares in Lantheus Holdings has caused some volatility in the company’s stock price. While the exact reasons behind this move are unknown, it will be interesting to see how Lantheus Holdings’ performance and stock price are affected in the coming months. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Lantheus Holdings. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Lantheus Holdings. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Lantheus Holdings. More…

Key Ratios Snapshot

Some of the financial key ratios for Lantheus Holdings are shown below. More…

Analysis – Lantheus Holdings Stock Fair Value Calculator

After thorough analysis of LANTHEUS HOLDINGS‘ financial statements, I have determined that the company’s intrinsic value is approximately $88.1 per share. This calculation was based on our proprietary Valuation Line, which takes into account various financial metrics and market conditions. Currently, LANTHEUS HOLDINGS’ stock is being traded at $107.36 per share. This indicates an overvaluation of 21.9% compared to its intrinsic value. This means that the market price of the stock is higher than what it is truly worth according to our analysis. Upon examination of LANTHEUS HOLDINGS’ financial statements, I noted that the company has been performing well in terms of revenue and profitability. However, there are some concerns regarding the company’s debt levels. LANTHEUS HOLDINGS’ current ratio, which measures a company’s ability to pay its short-term obligations, is relatively low compared to industry standards. This indicates potential liquidity issues and increases the company’s risk. In addition, LANTHEUS HOLDINGS has a high price-to-earnings ratio (P/E ratio) compared to its industry peers. This means that investors are paying a premium for the company’s earnings, which can be a warning sign for potential overvaluation. Overall, while LANTHEUS HOLDINGS has shown strong financial performance, there are certain red flags that should be taken into consideration when evaluating the company’s stock. Our proprietary Valuation Line suggests that the current market price may be inflated, and it may be prudent for investors to wait for a more reasonable entry point. More…

Peers

The company operates through two segments, Diagnostic Imaging and Therapeutic Imaging. The Diagnostic Imaging segment provides contrast media products and related services used in diagnostic imaging procedures. The Therapeutic Imaging segment provides nuclear imaging products and services used in molecular and nuclear medicine procedures. Lantheus Holdings Inc’s competitors include RadNet Inc, Akumin Inc, and Todos Medical Ltd. RadNet Inc is a provider of outpatient diagnostic imaging services in the United States. Akumin Inc is a provider of diagnostic imaging services in the United States and Canada. Todos Medical Ltd is a biotechnology company that develops and commercializes blood tests for the early detection of cancer.

– RadNet Inc ($NASDAQ:RDNT)

RadNet, Inc. is a national provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. As of December 31, 2020, RadNet operated a network of 284 outpatient imaging centers located in California, Delaware, Maryland, Massachusetts, New Jersey, New York and Virginia. RadNet’s core business is providing high-quality diagnostic imaging services, including magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, digital x-ray, diagnostic radiology and fluoroscopy, at its outpatient imaging centers.

– Akumin Inc ($NASDAQ:AKU)

Akumin Inc is a holding company that, through its subsidiaries, provides outpatient diagnostic imaging services in the United States. It operates through the following segments: Imaging Centers and Mobile Imaging. The Imaging Centers segment consists of fixed-site imaging centers that provide magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, general x-ray, and diagnostic cardiology services. The Mobile Imaging segment acquires, leases, and operates mobile imaging equipment that provides magnetic resonance imaging, computed tomography, ultrasound, and general x-ray services. The company was founded on December 12, 2005 and is headquartered in Dallas, TX.

– Todos Medical Ltd ($OTCPK:TOMDF)

Todos Medical Ltd has a market cap of 19.09M as of 2022, a Return on Equity of 43.06%. The company is engaged in the business of providing diagnostic products and services for the early detection, diagnosis and prognosis of cancer and other diseases. The company’s products and services include blood tests, tissue tests and imaging services. The company’s blood tests are used to detect the presence of cancer cells in the blood, while its tissue tests are used to detect the presence of cancer cells in the tissue. The company’s imaging services are used to detect the presence of cancer cells in the body.

Summary

Thrivent Financial for Lutherans drastically reduced its investment in Lantheus Holdings, Inc. during the second quarter, cutting its holdings by almost 91%. This move suggests that the financial institution may have lost confidence in the company’s performance and future prospects. It is worth noting that Lantheus Holdings, Inc. is a healthcare company that specializes in diagnostic and imaging agents.

However, without further details on the company’s background, it is difficult to determine the exact reason behind Thrivent Financial’s decision. Investors may want to carefully analyze the company’s financials and market trends before making any investment decisions in Lantheus Holdings, Inc.